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ORIGINAL ARTICLE
Background/Aims: Patients with diabetes are prone to coronary artery disease (CAD); however, the majority of
diabetic patients show normal coronary arteries. We examined differences in the clinical aspects of diabetic
patients with insignificant and with significant stenosis of the coronary artery. 
Methods: A total of 418 consecutive diabetic patients with stable angina who had undergone coronary
angiography from January 2004 to March 2007 were included in this study. Patients were subdivided into control
and CAD groups and then clinical characteristics and CAD-associated factors were evaluated. 
Results: A total of 92 (22%) patients were assigned to the control group and 326 (78%) patients were assigned to
the CAD group. Using univariate regression analysis, we found that patients with CAD were significantly older
(control vs. CAD; 59±21 vs. 64.7±33.7, years, p<0.001), had a longer duration of diabetes (8.2±21.8 vs.
10.2±29.8, years, p=0.027), higher titers of high sensitivity C-reactive protein (hsCRP; 0.3±6.79 vs. 0.9±12.6,
mg/dL, p=0.015), and increased hemoglobin A1c (HbA1c) levels (7.1±3.8 vs. 7.5±4.8, %, p=0.007) compared to
control patients. Multivariate regression analysis showed that only differences in age, hsCRP, and HbA1c were
statistically significant. When patients were subdivided into groups based on hsCRP levels (208 patients in the low
group [49.8%], 210 patients in the high group [50.2%]), we found that patients with higher hsCRP levels showed
more frequent multivessel disease.
Conclusions: In diabetic patients, age, hsCRP, and HbA1c were associated with stable CAD. Among these
factors, hsCRP levels were significantly correlated with multivessel involvement in diabetic CAD. Therefore, high
hsCRP levels may be a strong predictor for atherosclerotic progression of the coronary arteries in diabetic patients,
suggesting that regular screening tests should be performed. (Korean J Intern Med 2009;24:212-219)
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INTRODUCTION
The incidence and prevalence of diabetes mellitus (DM)
is rapidly increasing worldwide, due almost exclusively to
increases in non-insulin-dependent (type 2) DM. Type 2
DM represents more than 90% of all cases of diabetes
[1,2]. Cardiovascular complications are the leading cause
of morbidity among patients with diabetes, and ischemic
heart disease is the most common cause of death [3,4].
The excess risk for cardiovascular disease (CVD) is two- to
eight-fold higher in patients with diabetes compared to
non-diabetic individuals of similar age, sex, and ethnicity
[5-7]. Furthermore, among patients with coronary artery
disease (CAD), diabetes is associated with an increased
risk of developing acute coronary syndrome and an
increased risk of death after an acute myocardial
infarction [8,9]. The pathophysiological mechanism of
type 2 DM is insulin resistance, a proin-flammatory andLee HJ, et al. Inflammatory markers in DM patients with stable CAD    213
hypercoagulable state that predisposes patients to develop
CVD. Type 2 DM is associated with risk factors for
atherosclerosis including dyslipidemia, hypertension,
inflammation, and altered hemostasis [10]. 
To date, studies have documented that diabetic CVD is
increasing; however, questions regarding the temporal
relationship between diabetes and CVD, the metabolic
and cellular etiologic mechanisms underlying diabetic
CVD, and the most effective strategies for predicting and
reducing CVD risk in patients with diabetes remain
unanswered. Although the risk of CAD is high in diabetic
patients, most show normal coronary arteries. Here we
compared the clinical aspects of patients with insignificant
stenosis of the coronary artery to those of patients with
diabetes and CAD. Furthermore, we examined the asso-
ciation between CAD severity and high sensitivity C-
reactive protein (hsCRP) levels. 
METHODS
Patients and definitions
We retrospectively analyzed the clinical records and
catheterization reports of type 2 diabetic patients with
chest pain who underwent coronary angiography at
Kangnam St. Mary’s Hospital Seoul, Korea from January
Table 1. Comparison of clinical characteristics and association factors between control and CAD groups
Control CAD p value
(n=92) (n=326)
Age, years 59±21 64.7±33.7 <0.001
Sex 0.119
Male 40 (43.5) 184 (56.4)
Female 52 (56.5) 142 (43.6)
BMI, kg/m
2 25.4±9.1 24.5±11.2 0.102
DM duration, years 8.2±21.8 10.2±29.8 0.027
Type of DM treatment 0.072
Diet only 4 (4.3) 14 (4.3)
OHA 88 (95.7) 274 (84.1)
Insulin 0 (0) 20 (6.1)
OHA+Insulin 0 (0) 18 (5.5)
Hypertension 58 (63) 206 (63.2) 0.985
Smoking history 36 (39.1) 134 (41.1) 0.810
FBS, mg/dL 144.3±85.7 161.5±459.5 0.099
HbA1c, % 7.1±3.8 7.5±4.8 0.015
LVH 32 (34.8) 90 (27.6) 0.346
LVEF 0.056
≥50% 90 (97.8) 286 (87.7)
<50% 2  (2.2) 40  (12.3)
Proteinuria 16 (17.4) 76 (23.3) 0.392
hsCRP, mg/dL 0.3±6.79 0.9±12.6 0.007
Lipoprotein, mg/dL 25.8±108.4 25.7±148.9 0.061
Total-C, mg/dL 184.9±86.1 184.1±205.9 0.076
TG, mg/dL 197.2±369.8 179.4±991.6 0.730
LDL-C, mg/dL 104.0±139.4 112.8±108.2 0.094
HDL-C, mg/dL 44.4±72.6 39.2±25.8 0.356
Values are number (percentage) or mean±SD. 
CAD, coronary artery disease; BMI, body mass index; DM, diabetes mellitus; OHA, oral hypoglycemic agent; FBS, fasting blood sugar;
HbA1c, hemoglobin A1c; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; hsCRP, high sensitivity C-reactive
protein; Total-C, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.214 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
2004 to March 2007. In total, there were 541 consecutive
study subjects. The decision to perform coronary
angiography was based on symptoms consistent with the
diagnosis, an abnormal electrocar-diogram (ECG),
positive findings in standard exercise tests, or abnormal
findings in radionuclear studies. We subsequently
excluded 123 patients who had one or more of the
following characteristics: platelet count <100,000/mm
3;
serum creatinine levels >2.5 mg/dL; cardiogenic shock;
acute myocardial infarction within 48 hour; unstable
CAD; variant angina; history of coronary artery bypass
graft surgery; prior revascularization; malignancy;
autoimmune disease; or recent infectious disease.
Patients were further subdivided into a control (insignif-
icant CAD of <50% stenosis) and CAD group (significant
coronary arterial stenosis ≥50%). Baseline clinical
characteristics and CAD-associated factors among these
groups were investigated. The association between the
severity of CAD and hsCRP levels was also examined. In a
second analysis, the 418 patients were divided into low
and high hsCRP groups based on median hsCRP levels
(0.24 mg/dL). The physical examination included mea-
surements of height and weight, which were recorded
based on standardized methods, and body mass index,
which was calculated as weight (kg)/height (m
2). Patients
were also divided into two groups based on smoking
behavior (i.e., smokers and non-smokers). Patients who
had stopped smoking for 10 years or less were classified
as smokers. The diagnosis of DM was based on fasting
plasma glucose levels of ≥126 mg/dL (7.0 mmol/L) or 2-h
postprandial plasma glucose levels of ≥200 mg/dL (11.1
mmol/L). The type of diabetic treatment administered
was characterized, and patients were subdivided into four
groups based on treatment: diet only, oral hypoglycemic
agent, insulin, and combination therapy with oral hypo-
glycemic agents and insulin. A diagnosis of hypertension
was based on the Seventh Report of the Joint National
Committee on Detection, Evaluation, and Treatment of
High Blood Pressure, or current use of antihypertensive
drugs. Serum levels of lipoprotein, total cholesterol,
triglyceride, high-density lipoprotein cholesterol (HDL-c),
and low-density lipoprotein cholesterol (LDL-c) were
measured via enzymatic methods using an automatic
analyzer. Serum levels of hsCRP were measured by
immunonephelometry. 
Left ventricular hypertrophy was considered present
when the left ventricular mass index at initial echocar-
diographic M-mode measurement was greater than 134
g/m
2 in men and greater than 110 g/m
2 in women (based
on American Society of Echocardiography recommenda-
tions). Left ventricular ejection fraction (LVEF) was
determined by echocardiogram (Simpson’s method) and
patients were divided into two groups (>50% and <50%).
Proteinuria levels greater than 500 mg/day were defined
as overt proteinuria. Both right and left coronary arteries
were studied in at least two oblique projections (right
anterior oblique 30˚ and left anterior oblique 60˚). The
CAD group was defined as those patients who had at
least one coronary artery lesion that occupied at least
50% of the luminal diameter, as indicated by coronary
angiography. Patients with coronary artery lesions
occupying less than 50% of the luminal diameter were
assigned to the control group. 
Clinical factors associated with CAD were analyzed,
Table 2. Comparisons of clinical characteristics and association factors between control and CAD groups based
on multivariate regression analyses
Control CAD OR p value
(n=92) (n=326) (95%Cl)
Age, years 59±21 64.7±33.7 1.079 <0.001
(1.034-1.132)
HbA1c, % 7.1±3.8 7.5±4.8 1.386 0.010
(1.022-2.115)
hsCRP, mg/dL 0.3±6.79 0.9±12.6 1.797 0.006
(1.682-1.912)
DM duration, years 8.2±21.8 10.2±29.8 1.047 0.167
(1.016-1.105)
Values are number (percentage) or mean±SD. 
CAD, coronary artery disease; OR, odds ratio; HbA1c, hemoglobin A1c; hsCRP, high sensitivity C-reactive protein; DM, diabetes
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and patients were divided into two groups based on median
hsCRP levels (low and high). CAD-associated factors and
the severity of stable diabetic CAD were compared between
low and high hsCRP groups.
Statistical analysis
Statistical analyses were performed using the SPSS
statistical package, version 12.0 (SPSS Inc., Chicago, IL,
USA). Unless otherwise noted, all tests were two-tailed
and a p value less than 0.05 was considered significant.
Potential associations between clinical and biologic
parameters were tested by univariate and multivariate
regression analyses using a Student’s t-test or chi-square
test. All data are presented as means and standard
deviations.
Table 3. Comparison of clinical characteristics, association factor, and CAD severity between the low and high
hsCRP groups
All patients Low hsCRP group High hsCRP group p value*
(n=418) (n=208) (n=210)
Age, years 63.50±9.4 62.2±9.1 64.8±9.6 0.005
Male 224 (53.6) 108 (51.9) 116 (55.2) 0.498
BMI, kg/m
2 24.7±3.1 24.6±2.7 24.9±3.5 0.338
DM duration, years 9.81±7.5 8.9±6.3 10.7±8.4 0.012
DM treatment 0.467
Diet only 18 (4.2) 8 (3.8) 10 (4.8)
OHA 348 (83.3) 174 (83.7) 174 (82.9)
Insulin 30 (7.2) 12 (5.8) 18 (8.6)
OHA + Insulin 22 (5.3) 14 (6.7) 8 (3.8)
Hypertension 264 (63.2) 130 (62.5) 134 (63.8) 0.782
Smoking history 1 70 (40.7) 82 (39.4) 88 (41.9) 0.607
FBS, mg/dL 157.7±62.3 150.0±50.9 165.3±71.2 0.012
HbA1c, % 7.5±1.2 7.3±1.3 7.6±1.2 0.034
LVH 122 (29.2) 52 (25) 70 (33.3) 0.061
LVEF <0.001
≥50% 376 (90) 200 (96.2) 176 (83.8)
<50% 42 (10) 8 (3.8) 34 (16.2)
Proteinuria 92 (22) 34 (16.3) 58 (27.6) 0.005
Lipoprotein, mg/dL 25.7±22.8 23.4±19.8 27.9±25.3 0.044
Total-c, mg/dL 184.2±42.8 181.8±44.7 186.7±40.9 0.246
TG, mg/dL 183.3±136.3 190.9±137.9 175.7±134.4 0.254
LDL-C, mg/dL 110.8±34.9 104.2±35.0 117.3±33.6 <0.001
HDL-C, mg/dL 40.4±11.6 42.9±14.0 37.9±8.0 <0.001
Severity of CAD  <0.001
Normal 90 (21.5) 70 (33.7) 20 (9.5)
1 Vessel disease  114 (27.3) 50 (24.0) 64 (30.5)
2 Vessel disease  118 (28.2) 56 (26.9) 62 (29.5)
3 Vessel disease  96 (23) 32 (15.4) 64 (30.5)
Values are number (percentage) or mean±SD. 
CAD, coronary artery disease; hsCRP, high sensitivity C-reactive protein; BMI, body mass index; DM, diabetes mellitus; OHA, oral
hypoglycemic agent; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection
fraction; Total-C, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.
*statistical p value between the low hsCRP group and the high group.216 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
RESULTS
In total, 418 diabetic patients were enrolled in the study.
Based on angiography, 92 (22%) cases were assigned to
the control group and 326 (78%) cases were assigned to
the CAD group. Sample population characteristics with
respect to investigated risk parameters are presented in
Table 1. No relevant differences in baseline characteristics
(except age), medical history, or diabetic medication use
were significantly different between the control and CAD
groups. Based on univariate regression analysis, patients
with CAD were significantly older (control vs. CAD; 59±21
vs. 64.7±33.7, years, p<0.001) and had a longer duration
of diabetes (control vs. CAD; 8.2±21.8 vs. 10.2±29.8, years,
p=0.027), higher hsCRP titers (control vs. CAD; 0.3±6.79
vs. 0.9±12.6, mg/dL, p=0.015), and higher hemoglobin
A1c (HbA1c) levels (control vs. CAD; 7.1±3.8 vs. 7.5±4.8%,
p=0.007) compared to control patients. However, multi-
variate regression analysis showed that age, hsCRP, and
HbA1c were statistically different between the two groups
(Table 2). The duration of diabetes in the CAD group
tended to be longer; however, this difference was not
significantly different. No relevant differences were
observed in the degree of left ventricular hypertrophy, left
ventricular ejection fraction, fasting plasma glucose,
proteinuria, or lipid profiles between the groups.
We calculated odds ratios (OR) for factors associated
with CAD in diabetic patients between the control and
CAD groups. The OR for CAD and age was 1.079 (95%
confidence interval [CI], 1.034-1.132); for HbA1c was 1.386
(95% CI, 1.022-2.115); and for hsCRP was 1.797 (95% CI,
1.682-1.912; Table 2). 
Among the 418 diabetic patients, 208 (49.8%) had low
hsCRP levels and 210 (50.2%) had high hsCRP levels
based on median titer values (0.24 mg/dL). Patients in
the high hsCRP group were significantly older than
patients in the low hsCRP group (low hsCRP vs. high
hsCRP; 62.2±9.1 vs. 64.8±9.6 years, p<0.001). In addition,
fasting blood sugar (low hsCRP vs. high hsCRP; 150.0±
50.9 vs. 165.3±71.2 mg/dL, p=0.012) and HbA1c (low
hsCRP vs. high hsCRP; 7.3±1.3 vs. 7.6±1.2%, p=0.034)
were higher; the duration of diabetes (low hsCRP vs. high
hsCRP; 18.0 vs. 27.3 years, p=0.012) was longer; LDL-c
levels (low hsCRP vs. high hsCRP; 104.2±35.0 vs. 117.3±
33.6 mg/dL, p=0.022), lipoprotein levels (low hsCRP vs.
high hsCRP; 23.4±19.8 vs. 27.9±25.3 mg/dL, p=0.044),
and the amount of patients with <50% LVEF (low hsCRP
vs. high hsCRP; 3.8 vs. 16.2%, p<0.001) were higher; and
HDL-c levels (low hsCRP vs. high hsCRP; 42.9±14.0 vs.
37.9±8.0 mg/dL, p<0.001) were lower. Finally, both
proteinuria (low hsCRP vs. high hsCRP; 16.3 vs. 27.6%,
p=0.005) and multivessel disease (low hsCRP vs. high
hsCRP; normal: 33.7 vs. 9.5; 1 vessel disease: 24.0 vs.
30.5%, 2 vessel disease: 26.9 vs. 29.5, 3 vessel disease:
15.4 vs. 30.5%, respectively, p<0.001) was more frequent
(Table 3, Fig. 1). Multivariate logistic regression analysis
showed that the severity of CAD between the low hsCRP
group and the high group (normal vs. 1 vessel disease,
OR=4.480, p<0.001; normal vs. 2 vessel disease,
OR=3.875, p<0.001; normal vs. 3 vessel disease,
OR=7.000, p<0.001) was significantly different (Table 4). 
Table 4. Multivariate logistic regression analysis between the low hsCRP group and the high group
Severity of CAD OR 95% CI p value*
Normal <0.001
1 vessel disease 4.480 2.411-8.324 <0.001
2 vessel disease 3.875 2.096-7.163 <0.001
3 vessel disease 7.000 3.642-13.455 <0.001
hsCRP, high sensitivity C-reactive protein; CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.
*statistical p value between the low hsCRP group and the high group.
Figure 1. Comparison of CAD severity between the high hsCRP
group and the low hsCRP group. hsCRP, highly sensitive C-
reactive protein; vd, vessel disease; CAD, coronary artery disease.
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DISCUSSION
The prevalence, incidence, and mortality of all forms
of CVD were strikingly higher for people with diabetes
than those without diabetes [5-7]. According to the World
Health Organization, the prevalence of CVD in diabetic
patients ranges from 26 to 36% [11]. Our study also shows
a lower prevalence of significant CAD (22%) in diabetic
patients with stable CAD. 
Measurement of hsCRP, an inflammatory biomarker
that independently predicts future vascular events,
improves global classification of risk, regardless of LDL-c
levels [12-16]. In the Bezafibrate Infarction Prevention
(BIP) study [17], high CRP levels was a strong predictor
for subsequent ischemic stroke among patients with pre-
existing artherosclerotic disease; a greater than two-fold
increased risk was observed between the top versus
bottom tertiles. In the Inflammation and Carotid Artery-
Risk for Atherosclerosis study (ICARAS) [18], elevated
hsCRP levels indicated the systemic nature of progressive
atherosclerotic disease and suggested that patients with
enhanced inflammation are generally at high risk for
progression of artherosclerotic disease and may exhibit
multiple vulnerable lesions.
We presumed that, although the risk for CVD is high in
diabetics, patients often have insignificant coronary artery
stenosis. Therefore, we compared the clinical aspects of
insignificant stenosis in coronary artery patients to those
of diabetic patients with significant CAD. We found that
diabetic patients with stable CAD are significantly older
and have higher hsCRP titers and HbA1c levels compared
to control patients. One of the most important findings of
this report is that high hsCRP levels strongly predict an
increased risk for atherosclerotic progression among
groups of patients with diabetic stable CAD. Specifically,
a 1.797-fold increased risk was observed between the CAD
and control group after adjusting for potential confounding
variables. A meta-analysis of studies with long-term
follow-up data showed that the risk for stroke in healthy
individuals in the highest quartile of CRP concentrations
was nearly 1.7-fold higher than that of those in the lowest
quartile [19]. In a nested case-controlled study among
patients who had experienced a cerebrovascular event (the
Perindopril Protection Against Recurrent Stroke Study, or
PROGRESS [20]), the OR for a recurrent event associated
with the top versus bottom tertile was 1.39 for CRP. 
We also examined the association between CAD severity
and hsCRP titers in patients with low and high hsCRP
levels based on median level values. In patients with stable
diabetic CAD, multivessel disease was significantly
correlated with increased hsCRP levels (OR of three-vessel
disease=7.0 compared to normal vessel disease). A strong
prediction of risk was estimated in our study, as charac-
terized by the presence of atherosclerotic CAD. These
strong associations are likely applicable to diabetic popu-
lations at high risk for CAD in pre-existing atherosclerotic
disease.
Several pharmacological agents that are proven to reduce
vascular risk also reduce hsCRP levels. Among these, all
statins lower hsCRP, with more potent statins having
greater effects. On average, median hsCRP levels decline
15-25% after 6 weeks of therapy [21-23]. 
Current guidelines recommend screening for CAD in
diabetic patients with a high cardiovascular risk. The
American Diabetes Association (ADA) recommends cardiac
testing for diabetic patients with the following charac-
teristics: typical or atypical cardiac symptoms; resting
ECGs suggestive of ischemia or infarction; peripheral or
carotid occlusive arterial disease; a sedentary lifestyle; over
35 years old; plan to begin a vigorous exercise program; or
show traditional and diabetes-specific risk factors (lipid
profile, blood pressure, smoking, or with family history of
premature CAD, micro/macroalbuminuria) [24]. Another
guideline edited by the Société Française de Cardiologie/
Association de Langue Française pour l’Etude du Diabéte
et des Maladies métaboliques (SFC/ALFEDIAM) makes
similar recommendations [25]. These guidelines do not
emphasize the evaluation of inflammatory markers such
as hsCRP; however, based on our results, hsCRP is a good
surrogate marker for CAD. A prospective follow-up study
in diabetes showed that high CRP levels were associated
with an increased risk of major coronary events [26].
Therefore, we recommend that prevention should also
focus on patients with high CRP.
We are aware of several limitations to our study. It was
conducted at a single center and was not a randomized.
Therefore, it is necessary to validate these data with
multicenter-randomized studies. We considered hsCRP
levels a predictor of atherosclerotic progression; however,
we could not show long-term effects of hsCRP levels on
atherosclerotic progression and thus we should continue
to conduct follow-up on all patients involved in this study.
In January 2003, the American Heart Association and
the Centers for Disease Control released the following
new recommendations for CRP levels as a predictor of
CVD: low risk, <0.1 mg/dL; average risk, 0.1-0.3 mg/dL;218 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
and high risk, >0.3 mg/dL. In the Justification for the Use
of Statins in Primary prevention: An Intervention Trial
Evaluating Rosuvastatin (JUPITER) study [21,27], high
hsCRP levels were 0.2 mg/dL or higher. The cut-off point
of hsCRP levels is not clear; therefore, we divided patients
into two groups based on the median value measured.
Our median hsCRP level was 0.24 mg/dL, which was
greater than the cut-off point for the JUPITER study.
This discrepancy is thought to be mainly due to the
characteristics of our study group, namely, diabetic stable
CAD (we did not include all types of CAD in this study).
Patients with acute myocardial infarction and unstable
CAD were excluded from the study because CAD in the
acute phase shows increased expression of inflammatory
markers. The only inflammatory marker studied was
hsCRP, and thus further evaluations of other inflammatory
markers are warranted.
In conclusion, age and levels of HbA1c and hsCRP of
diabetic patients were associated with stable CAD, and
may be used as surrogate markers of CAD in diabetes.
High hsCRP levels were uniquely correlated with multi-
vessel disease in diabetic CAD. Therefore, high hsCRP
levels in patients with stable diabetic CAD may represent a
strong predictive factor for an increased risk of athero-
sclerotic progression in the coronary arteries. We suggest
that diabetic patients with high hsCRP levels require
regular screening tests for CAD (using noninvasive
methods or invasive coronary angiography) when there
are no other reasons for elevated hsCRP levels other
than atherosclerotic disease. Future studies will examine
the utility of these findings as a guide to monitor the pro-
gression of atherosclerotic disease and its subsequent
treatment. 
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